



Pharmaxis Ltd

ABN 75 082 811 630

Notice of Annual General Meeting

Notice is hereby given that the annual general meeting of the shareholders of Pharmaxis Ltd will be held at the Sheraton on the Park, 161 Elizabeth Street Sydney NSW on 15th November 2005 at 2.30pm.

Ordinary Business:

1. To receive and consider the financial report of the Company for the year ended 30 June 2005 and the related directors' reports, directors' declarations and auditors' reports.

Items 2-9 will be proposed as ordinary resolutions.

- 2. That Dr Carrie Hillyard be re-elected as a director of the Company.
- 3. That Mr Charles Kiefel be re-elected as a director of the Company.
- 4. That Mr Malcolm McComas be re-elected as a director of the Company.
- 5. That Dr Brett Charlton be granted 105,000 options under the Company's employee option plan.
- 6. That Mr Denis Hanley be granted 40,000 options under the Company's employee option plan.
- 7. That Mr Charles Kiefel be granted 20,000 options under the Company's employee option plan.
- 8. That Mr Malcolm McComas be granted 20,000 options under the Company's employee option plan.
- 9. That Dr Alan Robertson be granted 150,000 options under the Company's employee option plan.

Special Business

Item 10 will be proposed as a non binding vote.

10. That the remuneration report contained in the directors' report for the year ended 30 June 2005 be adopted.

Other Business

To deal with any other business that may be brought forward in accordance with the constitution and the Corporations Act.

Voting Restrictions

Resolutions 5 to 9

The Company will disregard any votes cast on resolutions 5 to 9 by:

- any director of the Company (except a director who is ineligible to participate in any employee incentive scheme in respect of the Company) and, if Australian Stock Exchange has expressed an opinion under rule 10.14.3 that approval is required for participation in an employee incentive scheme by anyone else, that person; and
- any of their associates.

However the Company need not disregard a vote if:

- it is cast by a person as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form; or
- it is cast by the person chairing the meeting as proxy for a person who is entitled to vote, in accordance with the directions on the proxy form to vote as the proxy decides.

By order of the Board

Mr David McGarvey Company Secretary 12th October 2005

Voting Entitlements

For the purpose of the Corporations Act, the Company has determined that all securities of the Company that are quoted securities at 7.00 pm Australian Eastern Standard Time on 11th November 2005 will be taken, for the purpose of the annual general meeting, to be held by the persons who held them at the time.

Proxies

A shareholder has the right to appoint a proxy, who need not be a shareholder of the Company. If a shareholder is entitled to two or more votes they may appoint two proxies and may specify the percentage of votes each proxy is appointed to exercise. The Proxy Form must be deposited at the share registry of the Company, Computershare Investor Services Pty Limited, located at Level 2, 60 Carrington Street, Sydney NSW 2000 or at the Company's Registered Office, Unit 2, 10 Rodborough Road, Frenchs Forest NSW 2086, or by facsimile to Computershare on (03) 9473 2118 or to the Company on (02) 9451 3622.

EXPLANATORY STATEMENT

item 1: Fi

Item 1: Financial, Directors' and Auditors' Reports, and Directors' Declarations

As required by section 317 of the Corporations Act 2001, the financial report of the Company, the directors' report and the auditors' report for the financial year ended 30 June 2005 will be laid before the meeting.

Item 2: Re-election of Dr Carrie Hillyard

Carrie Hillyard, Ph.D., has been a member of the board of directors of the Company since August 2002. Carrie has more than three decades of experience in managing all aspects of drug discovery and development at life science companies. Carrie's career extends from research in cancer and endocrinology at London University, through patenting and developing novel diagnostic technologies, to assisting entrepreneurs and early-stage life science companies. From 1997 to the present time, Carrie has served as a founder and partner at CM Capital Investments, a venture capital fund manager, where she heads the life sciences practice. Carrie is the inventor of six patent families, and has provided strategic guidance to pharmaceutical and biotechnology companies on licensing technology, managing collaborations and obtaining venture funding. Carrie has also advised the Australian government on science and technology matters and is a board member of the Australian Nuclear Science and Technology Organisation. Carrie serves on the board of directors of CathRx Ltd.

Carrie holds a joint B.Sc. in biochemistry and biology with honors from the University of London and a Ph.D. in medicine from the Royal Postgraduate Medical School in the U.K. Carrie is a Fellow of the Academy of Technological Sciences and Engineering and the recipient of the Centenary medal from the Australian Government.

If re-elected, Dr Carrie Hillyard's term of appointment will be until the third annual general meeting subsequent to her reelection or three years (whichever is longer), subject to the constitution of the Company (in particular the retirement by rotation provisions), the ASX Listing Rules and the Corporations Act 2001.

The directors (with Dr Carrie Hillyard abstaining) recommend that shareholders vote in favour of this resolution.

Item 3: Re-election of Mr Charles Kiefel

Charles Kiefel has been a member of the board of directors of the Company since May 2003. Charles has more than two decades of experience in finance and investment banking. From 1990 to 2000 Charles was Managing Director of Corporate Finance at ANZ Investment Bank. From 1986 to 1990, Charles was Director of Corporate Finance at Ord Minnett. From 1985 to 1986, Charles held positions at Lazard Brothers & Co. Ltd in the U.K. and Lazard Frere in New York. Charles serves on the board of directors of Universal Biosensors Pty Ltd, Military Superannuation & Benefits Board, WHTM Asset Management Ltd, and WHTM Capital Management Ltd.

Charles has a B.Com. from the University of New South Wales and is a Fellow of the Institute of Chartered Accountants in Australia.

If re-elected, Mr Charles Kiefel's term of appointment will be until the third annual general meeting subsequent to his re-election or three years (whichever is longer), subject to the constitution of the Company (in particular the retirement by rotation provisions), the ASX Listing Rules and the Corporations Act 2001.

The directors (with Mr Charles Kiefel abstaining) recommend that shareholders vote in favour of this resolution.

Item 4: Re-election of Mr Malcolm McComas

Malcolm McComas has been a member of the board of directors of the Company since July 2003. Malcolm has more than two decades of experience in investment banking, particularly in equity and debt finance, mergers and acquisitions, and privatizations. From 1999 to 2004, Malcolm was a director of Grant Samuel and currently serves as a consultant to their corporate advisory, property services and funds management group. During 1998, Malcolm served as a Managing Director at Salomon Smith Barney. From 1988 to 1997, Malcolm served as a Managing Director at County NatWest. Malcolm serves as a non-executive director of Australasian Investors Limited and non-executive chairman of Sunshine Heart Inc.

Malcolm holds a B.Ec. and a Bachelor of Laws from Monash University.

If re-elected, Mr Malcolm McComas' term of appointment will be until the third annual general meeting subsequent to his reelection or three years (whichever is longer), subject to the constitution of the Company (in particular the retirement by rotation provisions), the ASX Listing Rules and the Corporations Act 2001.

The directors (with Mr Malcolm McComas abstaining) recommend that shareholders vote in favour of this resolution.

Items 5 to 9 Grants of Options to Directors

Following a review of director and employee performance for the year ended 30 June 2005, on 5 August 2005 the board of directors of the Company resolved, subject to the receipt of the necessary shareholder approvals, to grant an aggregate maximum of 335,000 options to directors of the Company under the Company's employee option plan (**Plan**) on the basis set out below:-

- 105,000 options to Dr Brett Charlton an executive director of the Company;
- 40,000 options to Mr Denis Hanley the non executive chairman of the Company;
- 20,000 options to Charles Kiefel a non executive director;
- 20,000 options to Mr Malcolm McComas a non executive director; and
- 150,000 options to Dr Alan Robertson the chief executive officer of the Company.

The proposed options would be governed by the terms of the Plan and would be granted on terms generally consistent with the existing options granted by the Company since listing. The proposed options would expire on 4 August 2015. The options are proposed to be granted for no cash consideration and are exercisable at \$1.79 which represents the average closing price of the Company's ordinary shares on Australian Stock Exchange in the five trading days prior to 5 August 2005 (being the date on which the board of directors resolved to grant the options subject to receipt of the necessary shareholder approvals). The proposed options would vest in four equal tranches with the first quarter vesting on 30 June 2006, the second quarter vesting on 30 June 2007, the third quarter vesting on 30 June 2008 and the final quarter vesting on 30 June 2009. In respect of options issued to Dr Brett Charlton and Dr Alan Robertson, the vesting of the options is also subject to the achievement of annual performance targets set and approved by the Company's remuneration and nomination committee. The Company's remuneration and nomination committee may approve the vesting of all or only a portion of the relevant options. If a takeover offer is made for the Company, all options which have not yet vested, vest.

When exercisable, each option issued under the Plan entitles the holder to subscribe for one fully paid ordinary share in the capital of the Company. Each ordinary share issued on exercise of an option will rank equally with all other ordinary shares then on issue.

Subject to receipt of shareholder approval, the options would be granted as soon as practicable after the annual general meeting and in any event no later than 12 months from the date of the annual general meeting.

The Company will not receive any cash consideration on the grant of the options but would receive cash consideration on the exercise of the options. The consideration received on exercise of the options will be used for the Company's general corporate purposes. The Company is not providing any loans or other financial assistance in connection with the grant or exercise of the proposed options.

The grant of options to directors under the Plan requires the approval of shareholders under Listing Rule 10.14 of the Listing Rules of Australian Stock Exchange. Since listing on Australian Stock Exchange in November 2003, the Company has not granted options to directors under the Plan and has therefore not previously sought approval of shareholders to grant of options under the Listing Rules.

Resolutions 5 to 9 seek the necessary shareholder approvals to grant the options to Dr Brett Charlton, Mr Denis Hanley, Mr Charles Kiefel, Mr Malcolm McComas and Dr Alan Robertson under the Plan up to the maximum amounts specified in the resolutions. The directors (with Dr Brett Charlton abstaining in respect of resolution 5, Mr Denis Hanley abstaining in respect of resolution 6, Mr Charles Kiefel abstaining in respect of resolution 7, Mr Malcolm McComas abstaining in respect of resolution 8 and Dr Alan Robertson abstaining in respect of resolution 9) recommend that shareholders vote in favour of resolutions 5 to 9 (inclusive).

Item 10: Advisory vote in relation to remuneration report of the Company

Section 250(2) of the Corporations Act 2001 requires that shareholders of a listed company vote in respect of the remuneration report of the Company. The vote on the resolution is advisory only and does not bind the directors of the Company. The remuneration report is contained within the Directors' Report of the Company, on page 39 of the enclosed Annual Report.

QUESTIONS FROM SHAREHOLDERS

The annual general meeting of Pharmaxis Ltd will be held 15 November 2005. Shareholders are invited to register questions in advance of the meeting.

This form may also be used to submit written questions to the auditor if the question is relevant to the content of the auditor's report or the conduct of the audit of the annual financial report of the Company.

If you wish to submit a written question, it must be received no later than five business days before the date of the meeting. Shareholders may also ask questions of the board of directors and the auditor at the meeting.

Please return this form to Computershare Investor Services Pty Limited, located at Level 2, 60 Carrington Street, Sydney NSW 2000 or at the Company's Registered Office, Unit 2, 10 Rodborough Road, Frenchs Forest NSW 2086, or by facsimile to Computershare on (03) 9473 2118 or to the Company on (02) 9451 3622

Shar	eholder name				
Secu	urity holder Reference	Number (SRN)	or	Holder Identification Number	er (HIN)
		Please tick the applicab	ole box below if you	r question is a question for the	auditor of the Company
1.					
2.					
3.					





Pharmaxis Ltd

ABN 75 082 811 630

Mark this box with an 'X' if you have made any changes to your address details (see reverse)



All correspondence to:

Computershare Investor Services Pty Limited GPO Box 7045 Sydney New South Wales 2001 Australia

Enquiries (within Australia) 1300 855 080 (outside Australia) 61 3 9415 4000

Facsimile 61 3 9473 2500 www.computershare.com

Securityholder Reference Number (SRN)



I 1234567890

IND



Appointment of Proxy

I/We being a member/s of Pharmaxis Ltd and entitled to attend and vote hereby appoint



the Chairman of the Meeting (mark with an 'X')

OR



If you are not appointing the Chairman of the Meeting as your proxy please write here the full name of the individual or body corporate (excluding the registered Securityholder) you are appointing as your proxy.

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chairman of the Meeting, as my/our proxy to act generally at the meeting on my/our behalf and to vote in accordance with the following directions (or if no directions have been given, as the proxy sees fit) at the Annual General Meeting of Pharmaxis Ltd to be held at the Sheraton on the Park, 161 Elizabeth Street Sydney NSW on 15 November 2005 at 2.30 pm and at any adjournment of that meeting.





IMPORTANT: FOR ITEMS 5 TO 9 BELOW

If the Chairman of the Meeting is your nominated proxy, or may be appointed by default, and you have not directed your proxy how to vote on Items 5 to 9 below, please place a mark in this box. By marking this box you acknowledge that the Chairman of the Meeting may exercise your proxy even if he has an interest in the outcome of those items and that votes cast by him, other than as proxy holder, would be disregarded because of that interest. If you do not mark this box, and you have not directed your proxy how to vote, the Chairman of the Meeting will not cast your votes on Items 5 to 9 and your votes will not be counted in computing the required majority if a poll is called on these items. The Chairman of the Meeting intends to vote undirected proxies in favour of each of these items.

Voting directions to your proxy - please mark



to indicate your directions

		For	Against	Abstain*			For	Against	Abstain*
Item 2	That Dr Carrie Hillyard be re-elected as a director of the Company				Item 6	Grant of options to Mr Denis Hanley			
					Item 7	Grant of options to Mr Charles			
Item 3	That Mr Charles Kiefel be re-elected as a director of the					Kiefel			
	Company				Item 8	Grant of options to Mr			
	, ,					Malcolm McComas			
Item 4	That Mr Malcolm McComas be re-elected as a director of				Item 9	Grant of options to Dr Alan			
	the Company				ileili 3	Robertson			
Item 5	Grant of options to Dr Brett Charlton				Item 10	Adopt the remuneration report			
	Chanton								<u></u>

In addition to the intention advised above, the Chairman of the Meeting intends to vote undirected proxies in favour of each of the other items of business.

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and	Director	Director/Company Secretary

Contact Name

Contact Daytime Telephone

Date

_

PXS

19 P R

^{*} If you mark the Abstain box for a particular item, you are directing your proxy <u>not</u> to vote on your behalf on a show of hands or on a poll and your votes will not be counted in computing the required majority on a poll.

How to complete the Proxy Form

1 Your Address

This is your address as it appears on the company's share register. If this information is incorrect, please mark the box and make the correction on the form. Securityholders sponsored by a broker (in which case your reference number overleaf will commence with an 'x') should advise your broker of any changes. Please note, you cannot change ownership of your securities using this form.

2 Appointment of a Proxy

If you wish to appoint the Chairman of the Meeting as your proxy, mark the box. If the individual or body corporate you wish to appoint as your proxy is someone other than the Chairman of the Meeting please write the full name of that individual or body corporate in the space provided. If you leave this section blank, or your named proxy does not attend the meeting, the Chairman of the Meeting will be your proxy. A proxy need not be a securityholder of the company. Do not write the name of the issuer company or the registered securityholder in the space.

3 Votes on Items of Business

You may direct your proxy how to vote by placing a mark in one of the three boxes opposite each item of business. All your securities will be voted in accordance with such a direction unless you indicate only a portion of voting rights are to be voted on any item by inserting the percentage or number of securities you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses. If you mark more than one box on an item your vote on that item will be invalid.

4 Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote on a poll. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by telephoning the company's share registry or you may copy this form.

To appoint a second proxy you must:

- (a) on each of the first Proxy Form and the second Proxy Form state the percentage of your voting rights or number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.
- (b) return both forms together in the same envelope.

5 Signing Instructions

You must sign this form as follows in the spaces provided:

Individual: where the holding is in one name, the holder must sign.

Joint Holding: where the holding is in more than one name, all of the securityholders should sign.

Power of Attorney: to sign under Power of Attorney, you must have already lodged this document with the registry. If you have not

previously lodged this document for notation, please attach a certified photocopy of the Power of Attorney to this form

when you return it.

Companies: where the company has a Sole Director who is also the Sole Company Secretary, this form must be signed by that

person. If the company (pursuant to section 204A of the Corporations Act 2001) does not have a Company Secretary, a Sole Director can also sign alone. Otherwise this form must be signed by a Director jointly with either another Director

or a Company Secretary. Please indicate the office held by signing in the appropriate place.

If a representative of a corporate Securityholder or proxy is to attend the meeting the appropriate "Certificate of Appointment of Corporate Representative" should be produced prior to admission. A form of the certificate may be obtained from the company's share registry or at **www.computershare.com**.

Lodgement of a Proxy

This Proxy Form (and any Power of Attorney under which it is signed) must be received at an address given below no later than 48 hours before the commencement of the meeting at 2.30 pm on 15 November 2005. Any Proxy Form received after that time will not be valid for the scheduled meeting.

Documents may be lodged using the reply paid envelope or:

IN PERSON Registered Office - Unit 2, 10 Rodborough Road, Frenchs Forest NSW 2086

Share Registry - Computershare Investor Services Pty Limited, Level 2, 60 Carrington Street, Sydney NSW 2000 Australia

BY MAIL Registered Office - Unit 2, 10 Rodborough Road, Frenchs Forest NSW 2086

Share Registry - Computershare Investor Services Pty Limited, GPO Box 4195, Sydney NSW 2001 Australia

BY FAX Registered Office - 61 2 9451 3622

Share Registry - 61 3 9473 2118